|
Learn how to use IsoPSA to better determine which patients to defer for biopsy and which to monitor more closely. |
|
Join Us at AUA 2026
|
|
We’ll be exhibiting at AUA 2026 in Washington, DC and would welcome the opportunity to connect with you at the IsoPSA booth (#4111).
|
|
As you know, PSA lacks specificity. It cannot reliably distinguish clinically significant prostate cancer (csPCa) from benign conditions such as prostatitis, inflammation, BPH, or indolent disease.
|
|
The IsoPSA Test is different. Unlike PSA testing, it is an accurate, simple, and proven tool that can detect clinically significant disease today and stratify risk over time. This test improves specificity for prostate cancer, enhances MRI results, and provides insight into a patient’s risk of csPCa over the next 30 months.
|
|
To discover how it can improve your protocol for risk stratification, visit IsoPSA.com, stop by booth #4111 at AUA, or contact us for more information.
|
|
|
|
|
This material concerns the IsoPSA Test, a laboratory developed test (LDT) from Cleveland Diagnostics, Inc., which is performed by CLIA-certified laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA requirements. When offered as an LDT, the IsoPSA Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
|
|
|
|
